艾拉莫德联合甲氨蝶呤治疗活动性类风湿关节炎的临床研究(2)
参考文献：
[1]Arnett FC，Edworthy SM，Bloch DA，etal.The American Rheumatoid Association 1987 revised criteria for the classification of rheumatoid arthritis[J].Arthritis Rheum，1988，31(3)：315-324.
[2]Aletaha D，Ward MM，Machold KP，et a1.Remission and active disease jn rheumatnid arthritis：defining criteria for disease activity states[J].Arthritis Rheum，2005，52：2625-2636.
[3]Tanaka K，Shimotori T，Majino S，et al.Pharmacological studies on 3-formylamino-7-methylsulfonylamino-6-phenoxy-4H-1-benzopyran-4-one(T-614)，a novel antiinflammatory agent.3rd communication：the involvement of bradykinin in its analgesic actions[J]..J Pharmacobiodyn，1992，15(11)：641-647.
[4]Yamamoto M，Urata N，Yamamoto T，et a1.Effect of a disease.Modifying antirheumatic drug，iguratimod(T614)on inflammatory cytokine production[J].Jpn Pharmacol Ther，2007，35(9)：551-559.
[5]Tanaka K，Yamanloto T，Aikawa Y，et al.Inhibitory effects of an anti-rheumatic agent T-614 on immunoglobulin production by cultured B cells and rheumatoid synovial tissues engrafted into SCID mice.[J].Rheumatology(Oxford)，2003，42(11)：1365-1371.
[6] Lu LJ1， Bao CD， Dai M，etal. Multicenter， randomized， double-blind， controlledtrialoftreatmentofactive rheumatoid arthritis with T-614compared with methotrexate，Arthritis[J].Rheum， 2009，61(7)：979-987.
[7]HaraM1，AbeT，SugawaraS，et al.Long-term safety study of iguratimod in patients with rheumatoid arthritis[J].Mod Rheumatol，2007，17(1)：10-16.编辑/张燕, http://www.100md.com(白巧红)
[1]Arnett FC，Edworthy SM，Bloch DA，etal.The American Rheumatoid Association 1987 revised criteria for the classification of rheumatoid arthritis[J].Arthritis Rheum，1988，31(3)：315-324.
[2]Aletaha D，Ward MM，Machold KP，et a1.Remission and active disease jn rheumatnid arthritis：defining criteria for disease activity states[J].Arthritis Rheum，2005，52：2625-2636.
[3]Tanaka K，Shimotori T，Majino S，et al.Pharmacological studies on 3-formylamino-7-methylsulfonylamino-6-phenoxy-4H-1-benzopyran-4-one(T-614)，a novel antiinflammatory agent.3rd communication：the involvement of bradykinin in its analgesic actions[J]..J Pharmacobiodyn，1992，15(11)：641-647.
[4]Yamamoto M，Urata N，Yamamoto T，et a1.Effect of a disease.Modifying antirheumatic drug，iguratimod(T614)on inflammatory cytokine production[J].Jpn Pharmacol Ther，2007，35(9)：551-559.
[5]Tanaka K，Yamanloto T，Aikawa Y，et al.Inhibitory effects of an anti-rheumatic agent T-614 on immunoglobulin production by cultured B cells and rheumatoid synovial tissues engrafted into SCID mice.[J].Rheumatology(Oxford)，2003，42(11)：1365-1371.
[6] Lu LJ1， Bao CD， Dai M，etal. Multicenter， randomized， double-blind， controlledtrialoftreatmentofactive rheumatoid arthritis with T-614compared with methotrexate，Arthritis[J].Rheum， 2009，61(7)：979-987.
[7]HaraM1，AbeT，SugawaraS，et al.Long-term safety study of iguratimod in patients with rheumatoid arthritis[J].Mod Rheumatol，2007，17(1)：10-16.编辑/张燕, http://www.100md.com(白巧红)